Benefits of Attending
· Learn from leading experts in the field
· Understand the opportunities, threats and challenges in pharmacogenomics
· Identify the key issues surrounding personalised medicine
· Keep up with the recent trends in pharmacogenomics/genetics
· Take advantage of the networking opportunities
· Meet the key decision makers
|
|
A unique opportunity to learn from leading industry experts including:
Dr Richard Kramer, Executive Director, External Collaborations, Functional Genomics, Novartis
Dr Clet Niyikiza, Oncology Senior Research Scientist & Consultant, Eli Lilly
Dr Nicholas Dracopoli, Executive Director, Clinical Discovery Technologies, Bristol-Myers Squibb
Dr John Morrison, Head, Global Clinical Genomics, AstraZeneca
Dr Chris Chamberlain, Medical Genetics Expert, Genetics & Integrated Medicine, Roche
Dr Christian Lavedan, Director, Pharmacogenomics Lab, Novartis
Dr Michael Phillips, Senior Scientist, Department of Pharmacogenetics, Orchid
Biosciences
Dr Miles Flamenbaum, Director, Business Development (UK), Oxford GlycoSciences